• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

    24.12 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Mar 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2
    Open 24.12
    Bid (Size) 22.00 (300)
    Ask (Size) 25.16 (1,200)
    Prev. Close 24.12
    Today's Range 24.12 - 24.12
    52wk Range 11.86 - 31.77
    Shares Outstanding 50,241,789
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis (ARQT) Q4 2025 Earnings Call Transcript ↗
    Arcutis (ARQT) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings

    Performance

    YTD
    -16.8%
    -16.8%
    1 Month
    -5.7%
    -5.7%
    3 Month
    -19.5%
    -19.5%
    6 Month
    +51.3%
    +51.3%
    1 Year
    +80.0%
    +80.0%

    More News

    Read More
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Surpasses Q4 Estimates and Raises 2026 Sales Outlook ↗
    Via Chartmill
    News headline image
    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows Technical Breakout Setup ↗
    Via Chartmill
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows High-Growth Momentum and Strong Technical Setup ↗
    Via Chartmill
    News headline image
    Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit ↗
    Via The Motley Fool
    News headline image
    Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics (NASDAQ:ARQT) Combines High-Growth Momentum with Bullish Technical Setup ↗
    Via Chartmill
    News headline image
    Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares ↗
    Via The Motley Fool
    News headline image
    Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
    Via MarketMinute
    Topics ETFs Economy Intellectual Property
    News headline image
    This Biotech Stock Could Cure Your Portfolio's Pain ↗
    Via The Motley Fool
    News headline image
    ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Shows Strong Technical and Fundamental Momentum ↗
    Via Chartmill
    News headline image
    Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Shares in Arcutis Biotherapeutics Surged Again This Week ↗
    Via The Motley Fool
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
    Via Benzinga
    News headline image
    FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest ↗
    Via Benzinga
    News headline image
    Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum ↗
    Via Chartmill

    Frequently Asked Questions

    Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?
    Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.
    What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?
    Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?
    The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market
    What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?
    The current price of Arcutis Biotherapeutics, Inc. - Common stock is 24.12
    When was Arcutis Biotherapeutics, Inc. - Common stock last traded?
    The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 03/04/26 04:00 PM ET
    What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?
    The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.21B
    How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?
    Arcutis Biotherapeutics, Inc. - Common stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.